CTNM logo

CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

144
Mkt Cap
$502.29M
Volume
94,236.00
52W High
$16.33
52W Low
$3.35
PE Ratio
-5.69
CTNM Fundamentals
Price
$12.42
Prev Close
$12.96
Open
$12.96
50D MA
$13.77
Beta
0.54
Avg. Volume
378,712.14
EPS (Annual)
-$2.17
P/B
1.78
Rev/Employee
$0.00
$61.97
Loading...
Loading...
News
all
press releases
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Brokerages
Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold rec...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% Higher - Still a Buy?
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% Higher - Still a Buy...
MarketBeat·29d ago
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts
Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat...
MarketBeat·1mo ago
News Placeholder
Contineum Therapeutics, Inc. $CTNM Shares Sold by Baker BROS. Advisors LP
Baker BROS. Advisors LP decreased its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Free Report) by 75.1% during the 3rd quarter, according to the company in its most recent filing...
MarketBeat·1mo ago
News Placeholder
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company's clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a...
MarketBeat·1mo ago
News Placeholder
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·1mo ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird
Robert W. Baird raised their price target on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·2mo ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS
Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·2mo ago
News Placeholder
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·2mo ago
News Placeholder
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·2mo ago
<
1
2
...
>

Latest CTNM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.